The European Federation for Medicinal Chemistry (EFMC) is an independent association representing medicinal chemistry societies in Europe. Its objective is to advance the science of medicinal chemistry by promoting cooperation and networking, by providing training and mentoring, by rewarding scientific excellence, and by facilitating communication and influencing stakeholders.

Meetings  November 2017 Next

STOA Working Breakfast - Solving Antimicrobial Resistance

During the STOA Working Breakfast co-organised by the European Parliament´s STOA, EuCheMS, and EFMC on the 28 April 2016, researchers and several Members of the European Parliament analysed the global challenge of antimicrobial resistance and weighted the pros and cons of possible solutions.

Antimicrobial Resistance (AMR) is the ability of microorganisms to withstand attack by antimicrobial drugs such as antibiotics, antifungal or antivirals, and is a serious issue that threatens to render many of the treatments we use today ineffective in the future – from tuberculosis to HIV, from pneumonia to other common infections.

The STOA Working Breakfast was an outcome of the work of the EFMC Working group on “Influence on European science policy”, chaired by Anders Karlén, in collaboration with EuCheMS.

(please note that the outcomes will also soon be available at STOA´s website)

Workshop Outcomes – Forward Look

This workshop attracted a capacity audience including at least six MEPs. It was chaired by Paul Rübig MEP, Chair of STOA.

Clear recommendations emerged from the Workshop. These include:

  • Antimicrobial resistance, of which antibiotic resistance is a subset, is a current problem in Europe that could become much worse; it is an even more serious problem in developing countries.
  • Better use of current antimicrobials is essential. This should include:
    • Enforcement of the ban on using antimicrobials in agriculture for anything other than treating disease
    • A major advertising campaign to ensure prescribed doses of antimicrobials are taken to completion
    • Better diagnostics to help doctors identify the correct antimicrobial to use
    • Ensuring that all doctors know when antimicrobial treatment is required
  • In addition to the better use of current antimicrobials, novel antimicrobials are urgently needed to treat multiresistant microbes.
  • Pharmaceutical companies will not, on their own, tackle antimicrobial resistance, because there is presently a predicted negative return on investment for a new antimicrobial drug.
  • Antimicrobial resistance should not be considered as a problem to be addressed in isolation, but in conjunction with efforts to address other medical problems of major European concern that are currently not tackled effectively, including e.g. ageing related and psychiatric diseases.
  • There is thus an urgent need for a consortium to be created involving pharmaceutical companies, philanthropists, the EC, and national governments to provide leadership and funding to tackle this problem. This consortium should:
    • Set up 1-3 major focused hubs for medicinal chemistry research in fields including antibacterial/antimicrobial/anti-infective development. The centres should tackle several disease areas in order to ensure continuity of funding and critical mass of activity. Specialist activities, e.g. high throughput screening / crystallography could be carried out in well linked spokes, not necessarily within the hubs
    • in the area of new antimicrobials,
      • principally focus on classes of clinically validated antimicrobials and/or on clinically validated targets
      • be fully equipped for drug discovery and development, mechanistic studies and testing against clinical isolates
      • be equipped to perform in vitro ADMET, in vivo pharmacology and efficacy and DMPK studies either by in house or external capabilities
      • be able to provide leadership in terms of in vitro and in vivo pharmacology, pharmacodynamics, distribution, metabolism and formulation
      • be linked to excellent centres for fundamental research which should also be funded properly
      • be linked to excellent hospitals with research & teaching facilities
      • be able to have access to large populations with microbial infections for significant clinical trials, ideally locally or by partnership
    • fund innovative ideas in key areas wherever they arise
    • link all researchers in the field so that they share all results immediately they are available
    • ensure that some of their research is not hampered by patents and lawyers
  • Such a development is a natural evolution of world leading collaborative activities in Europe. It will cost in excess of €1 bn to fund each centre and its associated researchers.

Presentations:

Solving antibiotic resistance: an introductionDavid Cole-Hamilton, EuCheMS President

Making choices on antibiotics (presentation to be uploaded soon) – Chris Schofield, University of Oxford

What it there are no new antibiotics?Lloyd Czaplewski, Chemical Biology Ventures Ltd


M T W T F S S
30 31 01 02 03 04 05
06 07 08 09 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 01 02 03
All events   |  Future events

Job portal

15/11/2017
Early Stage Researcher in Medicinal Chemistry, University of Basel (UNIBAS), University of Utrecht (UU), PamGene: Department of Pharmaceutical Sciences (UNIBAS), Department of Chemical Biology & Drug Discovery (UU), Basel, Utrecht, 's-Hertogenbosch, Switzerland
read more


15/11/2017
Early Stage Researcher in Medicinal Chemistry, Lund University (ULUND), University of Basel (UNIBAS), RedGlead: Department of Chemistry (ULUND), Department of Pharmaceutical Sciences (UNIBAS), Lund, Basel, Sweden
read more


15/11/2017
Early Stage Researcher in Medicinal Chemistry, Faculty of Pharmacy, University of Ljubljana (UL), University of Utrecht (UU), PamGene: Chair of Pharmaceutical Chemistry (UL), Department of Chemical Biology & Drug Discovery (UU), Ljubljana, Utrecht, 's-Hertogenbosch, Slovenia
read more


15/11/2017
Early Stage Researcher in Medicinal Chemistry, University of Utrecht (UU), University of Ljubljana (UL), PamGene: Department of Chemical Biology & Drug Discovery (UU), Faculty of Pharmacy, Chair of Pharmaceutical Chemistry (UL), Utrecht, Ljubljana, 's-Hertogenbosch, The Netherlands
read more


15/11/2017
Early Stage Researcher in Medicinal Chemistry, University of Basel (UNIBAS), University of Ljubljana (UL), Glycopedia: Department of Pharmaceutical Sciences (UNIBAS), Faculty of Pharmacy, Chair of Pharmaceutical Chemistry (UL), Basel, Ljubljana, Grenoble, Switzerland
read more


15/11/2017
Early Stage Researcher in Medicinal Chemistry, Faculty of Pharmacy, University of Ljubljana (UL), Lund University (ULUND), SARomics, RedGlead: Chair of Pharmaceutical Chemistry (UL), Department of Chemistry (ULUND), Ljubljana, Lund, Slovenia
read more


15/11/2017
Early Stage Researcher in Medicinal Chemistry, Lund University (ULUND), Faculty of Pharmacy, University of Ljubljana (UL), SARomics: Department of Chemistry (ULUND), Chair of Pharmaceutical Chemistry (UL), Lund, Ljubljana, Sweden
read more


15/11/2017
Early Stage Researcher in Medicinal Chemistry, Università degli Studi di Milano (UMIL), Universiteit Utrecht (UU), PamGene: Department of Chemistry (UMIL), Department of Chemical Biology & Drug Discovery (UU), Milano, Utrecht, 's-Hertogenbosch, Italy
read more


15/11/2017
Early Stage Researcher in Medicinal Chemistry, Université Grenoble Alpes (UGA), Universiteit Utrecht (UU), PamGene: CERMAV (UGA), Department of Chemical Biology & Drug Discovery (UU), Gières, Utrecht, 's-Hertogenbosch, France
read more


15/11/2017
Early Stage Researcher in Medicinal Chemistry, University of Utrecht (UU), Université Grenoble Alpes (UGA), Glycopedia: Department of Chemical Biology & Drug Discovery (UU), CERMAV (UGA), Utrecht, Gières, Grenoble, The Netherlands
read more


15/11/2017
Early Stage Researcher in Medicinal Chemistry, Università degli Studi di Milano (UMIL), Université Grenoble Alpes (UGA), Glycopedia: Department of Chemistry (UMIL), CERMAV (UGA), Milano, Gières, Grenoble, Italy
read more


15/11/2017
Early Stage Researcher in Medicinal Chemistry, Université Grenoble Alpes (UGA), Università degli Studi di Milano (UMIL), Glycopedia: CERMAV (UGA), Department of Chemistry (UMIL), Gières, Milano, Grenoble, France
read more


15/09/2017
Research / Senior Scientist Medicinal Chemistry, UCB: Medicinal Chemistry, Braine - L'Alleud, Belgium
read more


15/09/2017
Principal Scientist Medicinal Chemistry, UCB: Medicinal Chemistry, Braine-L'Alleud, Belgium
read more


20/04/2017
Medicinal / Synthetic Organic Chemists, Concept Life Sciences: Drug Discovery, Sandwich, Kent, United Kingdom
read more


Job portal page

Follow us on Facebook

Follow us on Twitter

Follow us on LinkedIn

ChemBridgeBoehringer IngelheimNovartisProf Dr W. Th. Nauta FoundationPfizerServierRoche
 Prous Institute for Biomedical ResearchUCBJanssen R&DBayerMerck